All News
Autoimmune Disease Impact Report
Integrated Benefit Institute, a nonprofit independent research organization, has published its 2025 Autoimmune Disease Impact Report, which examines the health and productivity impacts of five prevalent and costly autoimmune conditions: rheumatoid arthritis, multiple sclerosis, inflammat
Read Article
Targeting Obesity in Rheumatic Disease Patients
Sattar et al. has published an informative overview of the effect of obesity on rheumatic and musculoskeletal diseases (RMDs). They estimate that nearly 70% of RMD patients are overweight or obese.
Read Article
Dr. Swamy Venuturupalli, a Community Practice Innovation Award recipient, is transforming telehealth in rheumatology! His project introduces an innovative app that empowers patients to examine their own joints—making high-quality telehealth a seamless part of care. https://t.co/R5M4jtVz5m
Rheumatology Research Foundation RheumResearch ( View Tweet)
#Thrombocytopenia is common in #antiphospholipid syndrome (APS), and is likely associated with more severe disease. Although the pathophysiology underlying thrombocytopenia in APS has yet to be definitively revealed, mechanisms that play a role (at least in subsets of patients) https://t.co/pUXmb1irbw
Alberto Giraldo alb_giraldo ( View Tweet)
THERE’S STILL TIME to join us for #SOTA25, April 4-6 in Chicago! Secure your seat TODAY for a weekend of #rheum education, connection, & innovation → https://t.co/DEmGVZO5Af https://t.co/1D2j2enA2X
Links:
American College of Rheumatology ACRheum ( View Tweet)
Of >105,000 participants with 30-year follow-up, only 9.3% achieved healthy aging (age 70, w/o any chronic diseases). Their diet was significantly associated with this outcome🧵 @NatureMedicine https://t.co/VHxmdLvoDe
Eric Topol EricTopol ( View Tweet)
• Don't be afraid of being different.
• Take risks.
• Be curious.
• Don't be afraid to fail.
• Work hard for the things you love the most. https://t.co/7OeB5WfnNy
Prof. Feynman ProfFeynman ( View Tweet)
Congratulation to all the MSIVs who matched last week - Looking forward to ya'll becoming RHEUMATOLOGISTs of the futre https://t.co/NAePO72j9Z
Dr. John Cush RheumNow ( View Tweet)
Disease activity during Pregnancy in Rheumatoid arthritis and Spondyloarthritis
A prospective French study of rheumatoid arthritis (RA) or spondyloarthritis (SpA) patients showed that most maintained stable disease activity during pregnancy, but over one-third flared and https://t.co/3k6ZJTybAb
Dr. John Cush RheumNow ( View Tweet)
Increasing Prevalence of Osteoporosis
Research published in Osteoporosis International studied NHANES data showed increasing trends in osteoporosis in the United States of America.
https://t.co/9Ic2e6kaFR https://t.co/tVmFAp7EVe
Dr. John Cush RheumNow ( View Tweet)
Full read Overview of the effects of Menopause and Estrogen on autoimmune disorders https://t.co/NpVPrnPT6x https://t.co/wt9f5D7WXL
Dr. John Cush RheumNow ( View Tweet)
Post hoc analysis of 5 ph III Belimumab RCTs (BLISS, etc, N=3086) on skin outcomes BILAG & SLEDAI-2K), BEL was superior to PBO (mcBILAG OR: 1.29; mcSLEDAI-2K OR: 1.37). Also if SLEDAI ≥10 & dsDNA+ pts. BEL prevented skin flares (HR 0.70) https://t.co/p1MVVf97Go https://t.co/qwWUyegpyi
Dr. John Cush RheumNow ( View Tweet)
55 myositis (IIM) pts studied Nailfold Capillaries, MSAbs, cytokines & IFN genes. MDA5(+) pts signif more dilated (DIL), giant & abnl morphology caps, w/ microhemorrhages (MH) vs ARS (+) pts. MH & DIL assoc w/ MX1, IFI27, IP-10, RANTES, GROα. Giant caps assoc w/ IFI27, SDF-1α, https://t.co/3WQL8Sw0rq
Dr. John Cush RheumNow ( View Tweet)
Veterans Admin (VA) EHR study of #RA-associated ILD (n 1047), matched 237 RA-ILD pts who Rx w/ TNFi vs 237 Rx w/ non-TNF biologics (mean age 68y; 92% male). Death & Resp hospitalisation were similar (adj HR 1·21, 1·27), as was mortality (1·15), Resp mortality (1·38) https://t.co/03LV5B4FSV
Dr. John Cush RheumNow ( View Tweet)
NP and PA Growth in the USA
Forbes has published a thoughtful perspective on the declining number of US physicians and the growth in the number of advanced practice providers or APPs in the US clinical workforce.
https://t.co/syQcSFIeMP https://t.co/wbkofNJxd0 https://t.co/2cY42RX6Xo
Dr. John Cush RheumNow ( View Tweet)
Adrenal Dysfunction after Steroids in PMR and GCA Patients
JAMA has published a study of PMR and GCA patients who stopped glucocorticoid (GC) therapy and noted a low (1.2%) risk of GC-induced adrenal insufficiency after planned cessation.
https://t.co/ZTaIQxs0ex https://t.co/LA5qji8Zj5
Dr. John Cush RheumNow ( View Tweet)
Mizoribine Effective in Lupus Nephritis
A randomized clinical trial has shown that oral mizoribine, a common immunosuppressant in Japan, was noninferior to intravenous cyclophosphamide (CTX) as induction therapy in patients with active lupus nephritis.
https://t.co/OWnGly4TUX https://t.co/zbPPH1n4lU
Dr. John Cush RheumNow ( View Tweet)
Systematic literature review of sleep Rx in Fibromyalgia - 47 RCTs, 11094 pts, found cognitive behavioral Tx (CBT) significantly benefitted insomnia, but not pain. Pregabalin & sodium oxybate had small effect, but Amitriptyline, milnacipran, & duloxetine showed no benefit for https://t.co/XG8cFlpQqq
Dr. John Cush RheumNow ( View Tweet)
J&J announced the FDA jas granted the investigational drug, nipocalimab (FcRn recpt Ab), with Fast Track designation for its study in adult patients with moderate-to-severe Sjögren’s disease https://t.co/5rEYHkGVp2 https://t.co/ny2dv6Jtr5
Dr. John Cush RheumNow ( View Tweet)
Glucocorticoid Toxicity Index
Dr. John Stone has led the effort to develop the GTI - glucocorticoid toxicity index. In this review article he acknowledges the need and benefit of steroids, but details a novel means to identify and limit the untoward effects of glucorticoids https://t.co/foTaoYrfDn
Dr. John Cush RheumNow ( View Tweet)